266 related articles for article (PubMed ID: 30633598)
1. Evidence for cross-protection but not type-replacement over the 11 years after human papillomavirus vaccine introduction.
Covert C; Ding L; Brown D; Franco EL; Bernstein DI; Kahn JA
Hum Vaccin Immunother; 2019; 15(7-8):1962-1969. PubMed ID: 30633598
[TBL] [Abstract][Full Text] [Related]
2. Non-Vaccine-Type Human Papillomavirus Prevalence After Vaccine Introduction: No Evidence for Type Replacement but Evidence for Cross-Protection.
Saccucci M; Franco EL; Ding L; Bernstein DI; Brown D; Kahn JA
Sex Transm Dis; 2018 Apr; 45(4):260-265. PubMed ID: 29465705
[TBL] [Abstract][Full Text] [Related]
3. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study.
Tabrizi SN; Brotherton JM; Kaldor JM; Skinner SR; Liu B; Bateson D; McNamee K; Garefalakis M; Phillips S; Cummins E; Malloy M; Garland SM
Lancet Infect Dis; 2014 Oct; 14(10):958-66. PubMed ID: 25107680
[TBL] [Abstract][Full Text] [Related]
4. Human Papillomavirus Vaccine Effectiveness and Herd Protection in Young Women.
Spinner C; Ding L; Bernstein DI; Brown DR; Franco EL; Covert C; Kahn JA
Pediatrics; 2019 Feb; 143(2):. PubMed ID: 30670582
[TBL] [Abstract][Full Text] [Related]
5. Substantial Decline in Vaccine-Type Human Papillomavirus (HPV) Among Vaccinated Young Women During the First 8 Years After HPV Vaccine Introduction in a Community.
Kahn JA; Widdice LE; Ding L; Huang B; Brown DR; Franco EL; Bernstein DI
Clin Infect Dis; 2016 Nov; 63(10):1281-1287. PubMed ID: 27655996
[TBL] [Abstract][Full Text] [Related]
6. Decline in vaccine-type human papillomavirus prevalence in young men from a Midwest metropolitan area of the United States over the six years after vaccine introduction.
Widdice LE; Bernstein DI; Franco EL; Ding L; Brown DR; Ermel AC; Higgins L; Kahn JA
Vaccine; 2019 Oct; 37(45):6832-6841. PubMed ID: 31582269
[TBL] [Abstract][Full Text] [Related]
7. No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors.
Woestenberg PJ; King AJ; van der Sande MA; Donken R; Leussink S; van der Klis FR; Hoebe CJ; Bogaards JA; van Benthem BH; ;
J Infect; 2017 Apr; 74(4):393-400. PubMed ID: 28126492
[TBL] [Abstract][Full Text] [Related]
8. Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy.
Carozzi F; Puliti D; Ocello C; Anastasio PS; Moliterni EA; Perinetti E; Serradell L; Burroni E; Confortini M; Mantellini P; Zappa M; Dominiak-Felden G
BMC Infect Dis; 2018 Jan; 18(1):38. PubMed ID: 29334901
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology of Any and Vaccine-Type Anogenital Human Papillomavirus Among 13-26-Year-Old Young Men After HPV Vaccine Introduction.
Chandler E; Ding L; Gorbach P; Franco EL; Brown DA; Widdice LE; Bernstein DI; Kahn JA
J Adolesc Health; 2018 Jul; 63(1):43-49. PubMed ID: 30060856
[TBL] [Abstract][Full Text] [Related]
10. Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study.
Chow EP; Danielewski JA; Fehler G; Tabrizi SN; Law MG; Bradshaw CS; Garland SM; Chen MY; Fairley CK
Lancet Infect Dis; 2015 Nov; 15(11):1314-23. PubMed ID: 26201300
[TBL] [Abstract][Full Text] [Related]
11. Declines in HPV vaccine type prevalence in women screened for cervical cancer in the United States: Evidence of direct and herd effects of vaccination.
Markowitz LE; Naleway AL; Lewis RM; Crane B; Querec TD; Weinmann S; Steinau M; Unger ER
Vaccine; 2019 Jun; 37(29):3918-3924. PubMed ID: 31160099
[TBL] [Abstract][Full Text] [Related]
12. High Effectiveness of the Bivalent Human Papillomavirus (HPV) Vaccine Against Incident and Persistent HPV Infections up to 6 Years After Vaccination in Young Dutch Women.
Donken R; King AJ; Bogaards JA; Woestenberg PJ; Meijer CJLM; de Melker HE
J Infect Dis; 2018 Apr; 217(10):1579-1589. PubMed ID: 29409034
[TBL] [Abstract][Full Text] [Related]
13. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study.
Kavanagh K; Pollock KG; Cuschieri K; Palmer T; Cameron RL; Watt C; Bhatia R; Moore C; Cubie H; Cruickshank M; Robertson C
Lancet Infect Dis; 2017 Dec; 17(12):1293-1302. PubMed ID: 28965955
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of bivalent and quadrivalent human papillomavirus vaccination in Luxembourg.
Latsuzbaia A; Arbyn M; Tapp J; Fischer M; Weyers S; Pesch P; Mossong J
Cancer Epidemiol; 2019 Dec; 63():101593. PubMed ID: 31499377
[TBL] [Abstract][Full Text] [Related]
15. Significantly Reduced Genoprevalence of Vaccine-Type HPV-16/18 Infections among Vaccinated Compared to Non-Vaccinated Young Women 5.5 Years after a Bivalent HPV-16/18 Vaccine (Cervarix®) Pilot Project in Uganda.
Kumakech E; Berggren V; Wabinga H; Lillsunde-Larsson G; Helenius G; Kaliff M; Karlsson M; Kirimunda S; Musubika C; Andersson S
PLoS One; 2016; 11(8):e0160099. PubMed ID: 27482705
[TBL] [Abstract][Full Text] [Related]
16. Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction.
Kahn JA; Brown DR; Ding L; Widdice LE; Shew ML; Glynn S; Bernstein DI
Pediatrics; 2012 Aug; 130(2):e249-56. PubMed ID: 22778297
[TBL] [Abstract][Full Text] [Related]
17. Low prevalence of vaccine-type HPV infections in young women following the implementation of a school-based and catch-up vaccination in Quebec, Canada.
Goggin P; Sauvageau C; Gilca V; Defay F; Lambert G; Mathieu-C S; Guenoun J; Comète E; Coutlée F
Hum Vaccin Immunother; 2018 Jan; 14(1):118-123. PubMed ID: 29049007
[TBL] [Abstract][Full Text] [Related]
18. Association between human papillomavirus vaccine status and sexually transmitted infection outcomes among females aged 18-35 with a history of sexual activity in the United States: A population survey-based cross-sectional analysis.
Closson K; Karim ME; Sadarangani M; Naus M; Ogilvie GS; Donken R
Vaccine; 2020 Dec; 38(52):8396-8404. PubMed ID: 33239227
[TBL] [Abstract][Full Text] [Related]
19. Who's Not Protected in the Herd? Factors Associated with Vaccine-Type HPV in Unvaccinated Women.
Smith C; Ding L; Gorbach PM; Franco EL; Kahn JA
J Pediatr Adolesc Gynecol; 2018 Apr; 31(2):89-93. PubMed ID: 28943220
[TBL] [Abstract][Full Text] [Related]
20. Assessment of herd effects among women and heterosexual men after girls-only HPV16/18 vaccination in the Netherlands: A repeated cross-sectional study.
Woestenberg PJ; Bogaards JA; King AJ; Leussink S; van der Sande MA; Hoebe CJ; van Benthem BH;
Int J Cancer; 2019 Jun; 144(11):2718-2727. PubMed ID: 30426502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]